In this issue:
Dual-target gene therapy in PD
Multimodal biomarker strategy for diagnosing neurodegenerative parkinsonism
Microbiome PD signature in healthy and genetically at-risk individuals
LRRK2-targeting antisense oligonucleotide for PD
C3-microglial axis in depression of PD
Transcranial temporal interference stimulation targeting STN for PD motor symptoms
MRGFUS pallidothalamic tractotomy for motor complications of PD
Neuropsychiatric events with foslevodopa-foscarbidopa continuous subcutaneous infusions
Tavapadon as adjunctive PD treatment
Fixed-dose tavapadon for early PD
Please login below to download this issue (PDF)